{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:15:51Z","timestamp":1790363751141,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W026686\/1"],"award-info":[{"award-number":["MR\/W026686\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Promising blood-based biomarkers of neuropathology have emerged with potential for therapeutic development and disease monitoring. However, these tools will require specialist tertiary services for integration into clinical management. Remote sampling for biomarker assessment could reduce burden of in-person clinical visits for such tests as well as increasing the sampling frequency and patient geographical outreach. Here, we evaluated a finger-prick blood collection approach for remote quantification of neurofilament light (NfL), a candidate blood-based biomarker evident in various neurological disorders, and other exploratory markers of neuronal injury and neuroinflammation (GFAP, tau). Matched samples from venepuncture and finger-prick were collected and processed into plasma and\/or serum to directly compare analyte levels from a multi-disease discovery cohort (<jats:italic>n\u2009=\u2009<\/jats:italic>54 healthy controls; <jats:italic>n\u2009=\u2009<\/jats:italic>57 Huntington\u2019s disease (HD); <jats:italic>n\u2009=\u2009<\/jats:italic>34 multiple sclerosis; <jats:italic>n\u2009=\u2009<\/jats:italic>7 amyotrophic lateral sclerosis; <jats:italic>n\u2009=\u2009<\/jats:italic>11 Parkinson\u2019s disease), and a HD confirmatory cohort (<jats:italic>n\u2009=\u2009<\/jats:italic>57 healthy controls; <jats:italic>n\u2009=\u2009<\/jats:italic>64 HD). Two delayed processing conditions were compared, three- and seven-day delay, simulating ambient shipment. Capillary NfL and GFAP concentrations were equivalent to those in venous serum and plasma in the multi-disease discovery cohort and HD confirmatory cohort. Only NfL remained stable after a seven-day processing delay in both venous and capillary serum samples. Using NfL concentrations from capillary blood, we replicated previously published disease group differences measured in venous blood. This data supports our finger-prick approach for remote collection and quantification of NfL. With the widespread applications for NfL across the spectrum of neurological disorders, this has the potential to transform disease monitoring, prognosis, and therapeutic development within clinical practice and research.<\/jats:p>","DOI":"10.1007\/s00415-025-13232-8","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:13:26Z","timestamp":1752149606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases"],"prefix":"10.1007","volume":"272","author":[{"given":"Annabelle","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexiane","family":"Touz\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mena","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Thackeray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Fayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Broom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Z.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brook","family":"Huxford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Donkor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Camboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamalesh C.","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Zirra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rita","family":"Gameiro Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Sorrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Zampedri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Mangion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batoul","family":"Fneich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Noyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Chataway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-4273","authenticated-orcid":false,"given":"Lauren M.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"4","key":"13232_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","volume":"101","author":"D Alcolea","year":"2023","unstructured":"Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lle\u00f3 A (2023) Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist. Neurology 101(4):172\u2013180","journal-title":"Neurology"},{"issue":"4","key":"13232_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/ane.13700","volume":"146","author":"HR Morris","year":"2022","unstructured":"Morris HR (2022) Blood based biomarkers for movement disorders. Acta Neurol Scand 146(4):353","journal-title":"Acta Neurol Scand"},{"issue":"26","key":"13232_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100549","volume":"1","author":"F Yasuno","year":"2022","unstructured":"Yasuno F, Watanabe A, Kimura Y, Yamauchi Y, Ogata A, Ikenuma H et al (2022) Estimation of blood-based biomarkers of glial activation related to neuroinflammation. Brain Behav Immun Health 1(26):100549","journal-title":"Brain Behav Immun Health"},{"issue":"3","key":"13232_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1474-4422(13)70030-9","volume":"12","author":"T Dehnel","year":"2013","unstructured":"Dehnel T (2013) The European dementia prevention initiative. Lancet Neurol 12(3):227\u2013228","journal-title":"Lancet Neurol"},{"issue":"8","key":"13232_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/sextrans-2019-053992","volume":"95","author":"E Wilson","year":"2019","unstructured":"Wilson E, Leyrat C, Baraitser P, Free C (2019) Does internet-accessed STI (e-STI) testing increase testing uptake for chlamydia and other STIs among a young population who have never tested? Secondary analyses of data from a randomised controlled trial. Sex Transm Infect 95(8):569\u2013574","journal-title":"Sex Transm Infect"},{"issue":"9","key":"13232_CR6","doi-asserted-by":"publisher","first-page":"75091","DOI":"10.1371\/journal.pone.0075091","volume":"8","author":"J Gaiottino","year":"2013","unstructured":"Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A et al (2013) Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 8(9):75091","journal-title":"PLoS ONE"},{"issue":"8","key":"13232_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol 16(8):601","journal-title":"Lancet Neurol"},{"issue":"458","key":"13232_CR8","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1126\/scitranslmed.aat7108","volume":"10","author":"LM Byrne","year":"2018","unstructured":"Byrne LM, Rodrigues FB, Johnson EB, Wijeratne PA, De Vita E, Alexander DC et al (2018) Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci Transl Med 10(458):7108. https:\/\/doi.org\/10.1126\/scitranslmed.aat7108","journal-title":"Sci Transl Med"},{"issue":"6","key":"13232_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Sch\u00e4delin S, Giardiello A et al (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81(6):857","journal-title":"Ann Neurol"},{"issue":"2","key":"13232_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/ene.14063","volume":"27","author":"E Thouvenot","year":"2020","unstructured":"Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R et al (2020) Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol 27(2):251\u2013257","journal-title":"Eur J Neurol"},{"issue":"13","key":"13232_CR11","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IOC, Dick KM, Brotherhood E, Gordon E, Fellows A et al (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87(13):1329\u20131336","journal-title":"Neurology"},{"issue":"5","key":"13232_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Weiner MW, Aisen P et al (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 74(5):557\u2013566","journal-title":"JAMA Neurol"},{"issue":"22","key":"13232_CR13","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","volume":"84","author":"CH Lu","year":"2015","unstructured":"Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N et al (2015) Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84(22):2247","journal-title":"Neurology"},{"issue":"6","key":"13232_CR14","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","volume":"19","author":"RI Scahill","year":"2020","unstructured":"Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C et al (2020) Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington\u2019s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol 19(6):502\u2013512","journal-title":"Lancet Neurol"},{"issue":"13","key":"13232_CR15","doi-asserted-by":"publisher","first-page":"E1479","DOI":"10.1212\/WNL.0000000000007179","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM, Van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, Bloem BR et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92(13):E1479\u2013E1486","journal-title":"Neurology"},{"issue":"12","key":"13232_CR16","first-page":"1324","volume":"90","author":"T Sejbaek","year":"2019","unstructured":"Sejbaek T, Nielsen HH, Penner N, Plavina T, Mendoza JP, Martin NA et al (2019) Original research: dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment na\u00efve relapsing MS patients. J Neurol Neurosurg Psychiatry 90(12):1324","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13232_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.braindev.2023.07.005","volume":"45","author":"G Seo","year":"2023","unstructured":"Seo G, Kim S, Byun JC, Kwon S, Lee YJ (2023) Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen. Brain Dev 45:554\u2013563","journal-title":"Brain Dev"},{"issue":"6","key":"13232_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/d41573-023-00083-z","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A (2023) NfL makes regulatory debut as neurodegenerative disease biomarker. Nat Rev Drug Discov 22(6):431\u2013434","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"13232_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"V Lombardi","year":"2020","unstructured":"Lombardi V, Carassiti D, Giovannoni G, Lu CH, Adiutori R, Malaspina A (2020) The potential of neurofilaments analysis using dry-blood and plasma spots. Sci Rep 10(1):1\u201312","journal-title":"Sci Rep"},{"issue":"1","key":"13232_CR20","first-page":"21","volume":"13","author":"J Simr\u00e9n","year":"2021","unstructured":"Simr\u00e9n J, Ashton NJ, Blennow K, Zetterberg H (2021) Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre-analytical conditions. Alzheimer\u2019s Dement 13(1):21","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"13232_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-77098-8","volume":"10","author":"P Altmann","year":"2020","unstructured":"Altmann P, Leutmezer F, Zach H, Wurm R, Stattmann M, Ponleitner M et al (2020) Serum neurofilament light chain withstands delayed freezing and repeated thawing. Sci Rep 10(1):1\u20138","journal-title":"Sci Rep"},{"issue":"1","key":"13232_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-90639-z","volume":"11","author":"P Altmann","year":"2021","unstructured":"Altmann P, Ponleitner M, Rommer PS, Haslacher H, Mucher P, Leutmezer F et al (2021) Seven day pre-analytical stability of serum and plasma neurofilament light chain. Sci Rep 11(1):1\u20138","journal-title":"Sci Rep"},{"issue":"2","key":"13232_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"K Kieburtz","year":"1996","unstructured":"Kieburtz K (1996) Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov Disord 11(2):136\u2013142. https:\/\/doi.org\/10.1002\/mds.870110204","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"13232_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169(1\u20132):13\u201321","journal-title":"J Neurol Sci"},{"issue":"2","key":"13232_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"4","key":"13232_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/brain\/awf080","volume":"125","author":"AJ Hughes","year":"2002","unstructured":"Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125(4):861\u2013870","journal-title":"Brain"},{"key":"13232_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5535826","author":"M Keshtkarjahromi","year":"2022","unstructured":"Keshtkarjahromi M, Abraham DS, Gruber-Baldini AL, Schrader K, Reich SG, Savitt JM et al (2022) Confirming Parkinson disease diagnosis: patterns of diagnostic changes by movement disorder specialists. Parkinsons Dis. https:\/\/doi.org\/10.1155\/2022\/5535826","journal-title":"Parkinsons Dis"},{"issue":"12","key":"13232_CR28","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601","journal-title":"Mov Disord"},{"key":"13232_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41591-024-03424-6","volume":"31","author":"RI Scahill","year":"2025","unstructured":"Scahill RI, Farag M, Murphy MJ, Hobbs NZ, Leocadi M, Langley C et al (2025) Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington\u2019s disease decades before clinical motor diagnosis. Nat Med 31:807\u2013818","journal-title":"Nat Med"},{"issue":"574","key":"13232_CR30","doi-asserted-by":"publisher","first-page":"ebac2888","DOI":"10.1126\/scitranslmed.abc2888","volume":"12","author":"FB Rodrigues","year":"2020","unstructured":"Rodrigues FB, Byrne LM, Tortelli R, Johnson EB, Wijeratne PA, Arridge M et al (2020) Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease. Sci Transl Med 12(574):ebac2888","journal-title":"Sci Transl Med"},{"key":"13232_CR31","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/alz.13697","volume":"20","author":"H Huber","year":"2024","unstructured":"Huber H, Blennow K, Zetterberg H, Boada M, Jeromin A, Weninger H et al (2024) Biomarkers of Alzheimer\u2019s disease and neurodegeneration in dried blood spots: a new collection method for remote settings. Alzheimer\u2019s Dement 20:2340","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"13232_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-32480-0","volume":"13","author":"P Youssef","year":"2023","unstructured":"Youssef P, Hughes L, Kim WS, Halliday GM, Lewis SJG, Cooper A et al (2023) Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson\u2019s disease biomarkers using multiplexed single molecule counting. Sci Rep 13(1):1\u201311","journal-title":"Sci Rep"},{"issue":"11","key":"13232_CR33","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/acn3.51676","volume":"9","author":"L Vermunt","year":"2022","unstructured":"Vermunt L, Otte M, Verberk IMW, Killestein J, Lemstra AW, van der Flier WM et al (2022) Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. Ann Clin Transl Neurol 9(11):1832","journal-title":"Ann Clin Transl Neurol"},{"key":"13232_CR34","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3389\/fneur.2020.01054","volume":"11","author":"NA Huebschmann","year":"2020","unstructured":"Huebschmann NA, Luoto TM, Karr JE, Berghem K, Blennow K, Zetterberg H et al (2020) Comparing glial fibrillary acidic protein (GFAP) in serum and plasma following mild traumatic brain injury in older adults. Front Neurol 11:1054","journal-title":"Front Neurol"},{"key":"13232_CR35","doi-asserted-by":"publisher","first-page":"894119","DOI":"10.3389\/fneur.2022.894119","volume":"13","author":"N R\u00fcbsamen","year":"2022","unstructured":"R\u00fcbsamen N, Willemse EAJ, Leppert D, Wiendl H, Nauck M, Karch A et al (2022) A method to combine neurofilament light measurements from blood serum and plasma in clinical and population-based studies. Front Neurol 13:894119","journal-title":"Front Neurol"},{"issue":"23","key":"13232_CR36","doi-asserted-by":"publisher","first-page":"E2448","DOI":"10.1212\/WNL.0000000000207957","volume":"101","author":"ES Sotirchos","year":"2023","unstructured":"Sotirchos ES, Hu C, Smith MD, Lord HN, Duval AL, Arrambide G et al (2023) Agreement between published reference resources for neurofilament light chain levels in people with multiple sclerosis. Neurology 101(23):E2448\u2013E2453","journal-title":"Neurology"},{"issue":"1","key":"13232_CR37","doi-asserted-by":"publisher","first-page":"e12168","DOI":"10.1002\/dad2.12168","volume":"13","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Su\u00e1rez-Calvet M, Karikari TK, Lantero-Rodriguez J, Snellman A, Sauer M et al (2021) Effects of pre-analytical procedures on blood biomarkers for Alzheimer\u2019s pathophysiology, glial activation, and neurodegeneration. Alzheimers Dement (Amst) 13(1):e12168","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"13232_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/00365513.2020.1730434","volume":"80","author":"CVB Hviid","year":"2020","unstructured":"Hviid CVB, Knudsen CS, Parkner T (2020) Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. Scand J Clin Lab Invest 80(4):291\u2013295","journal-title":"Scand J Clin Lab Invest"},{"issue":"1","key":"13232_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.11613\/BM.2011.015","volume":"21","author":"M Koseoglu","year":"2011","unstructured":"Koseoglu M, Hur A, Atay A, \u00c7uhadar S (2011) Effects of hemolysis interferences on routine biochemistry parameters. Biochem Med (Zagreb) 21(1):79\u201385","journal-title":"Biochem Med (Zagreb)"},{"issue":"1","key":"13232_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7589\/0090-3558-45.1.73","volume":"45","author":"Y Roman","year":"2009","unstructured":"Roman Y, Bomsel-Demontoy MC, Levrier J, Chaste-Duvernoy D, Jaime MS (2009) Effect of hemolysis on plasma protein levels and plasma electrophoresis in birds. J Wildl Dis 45(1):73\u201380","journal-title":"J Wildl Dis"},{"issue":"16","key":"13232_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.959261","volume":"1","author":"Y Liu","year":"2022","unstructured":"Liu Y, Dou K, Xue L, Li X, Xie A (2022) Neurofilament light as a biomarker for motor decline in Parkinson\u2019s disease. Front Neurosci 1(16):959261","journal-title":"Front Neurosci"},{"issue":"1","key":"13232_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1212\/NXI.0000000000000422","volume":"5","author":"KN Varhaug","year":"2018","unstructured":"Varhaug KN, Barro C, Bj\u00f8rnevik K, Myhr KM, Torkildsen \u00d8, Wergeland S et al (2018) Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 5(1):422","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"13232_CR43","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1212\/WNL.0000000000009559","volume":"95","author":"M Benatar","year":"2020","unstructured":"Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R et al (2020) Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95(1):e59-69","journal-title":"Neurology"},{"issue":"3","key":"13232_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/01926233231180179","volume":"51","author":"D Theil","year":"2023","unstructured":"Theil D, Kuhle J, Brees D, Tritto E, Pognan F, Frieauff W et al (2023) Neurofilament light chain: a translational safety biomarker for drug-induced peripheral neurotoxicity. Toxicol Pathol 51(3):135\u2013147","journal-title":"Toxicol Pathol"},{"issue":"7","key":"13232_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ et al (2022) Potential disease modifying therapies for Huntington\u2019s disease, lessons learned and future opportunities. Lancet Neurol 21(7):645","journal-title":"Lancet Neurol"},{"key":"13232_CR46","doi-asserted-by":"publisher","first-page":"104710","DOI":"10.1016\/j.ebiom.2023.104710","volume":"94","author":"C Sampaio","year":"2023","unstructured":"Sampaio C, Wilkinson HA (2023) Facilitating Huntington\u2019s disease research: plasma neurofilament levels as a promising enrichment biomarker for HD-ISS stage 1. EBioMedicine 94:104710","journal-title":"EBioMedicine"},{"issue":"8","key":"13232_CR47","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL et al (2022) Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease\u2013related blood-based biomarkers: Results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimer\u2019s & Dementia. 18(8):1484\u20131497. https:\/\/doi.org\/10.1002\/alz.12510","journal-title":"Alzheimer\u2019s & Dementia."}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13232-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13232-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13232-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:22:42Z","timestamp":1756894962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13232-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["13232"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13232-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LMB holds consultancy contracts with Annexon Biosciences, Remix Therapeutics, PTC Therapeutics, Alchemab Therapeutics, Latus Bio, and LoQus23 Therapeutics Ltd via UCL Consultants Ltd. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). AN received consultancy fees during the design phase of AccessPD and reports consultancy and personal fees from AstraZeneca, AbbVie, Profile, Roche, Biogen, UCB, Bial, Charco Neurotech, Alchemab, Sosei Heptares and Britannia, outside the submitted work. AN is an Associate Editor for the Journal of Parkinson\u2019s Disease. In the last 3\u00a0years, JC has received support from the Health Technology Assessment (HTA) Programme (National Institute for Health Research, NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the NIHR University College London Hospitals (UCLH) Biomedical Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by MS Canada. A local principal investigator for commercial trials funded by: Ionis and Roche; and has taken part in advisory boards\/consultancy for Biogen, Contineum Therapeutics, Lucid, Merck, NervGen, Novartis and Roche. SJT reports that over the past 3\u00a0years consultancy fees for advisory services were paid to University College London Consultants, a wholly-owned subsidiary of University College London from the following companies:\u00a0Alchemab, Alnylam Pharmaceuticals, Annexon Bioscience, Arrowhead, Atalanta Therapeutics, Biogen, Catapult, Design Therapeutics, F. Hoffman-La Roche, Ipsen, Iris Medicine, Latus Bio, LifeEdit, Novartis Pharma, Pfizer, Prilenia, Prime Global, PTC Therapeutics, Remix, Rgenta Therapeutics, SkyHawk, Takeda Pharmaceuticals, Triplet Therapeutics, UniQure Biopharma, Vertex Pharmaceuticals, Vico Therapeutics, Wave Life Sciences.\u00a0SJT has also consulted for Abingworth, Ascidian Therapeutics, EQT, Cure Ventures, FunctionRX, Harrisson & Star, and IQVIA through the office of Celtic Phenomenon. In the past 3\u00a0years, University College London Hospitals NHS Foundation Trust, Professor Tabrizi\u2019s host clinical institution, received funding to run clinical trials for Alnylam Pharmaceuticals, F. Hoffman-La Roche, Novartis Pharma, PTC Therapeutics, and UniQure Biopharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study complies with the Declaration of Helsinki and was approved by local ethics committees including The National Hospital for Neurology and Neurosurgery and the Institute of Neurology Joint Research Ethics Committee (HD and controls; ref: 03\/N008); London\u2014City & East Research Ethics committee (ALS, MS; ref: 09\/H0703\/27); South West \u2013 Central Bristol Research Ethics Committee (PD: PR 18\/SW\/0255).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants within the study gave written informed consent before blood collection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"501"}}